Introduction: The MYC/MAX/MAD transcriptional axis is essential for regulating cellular proliferation, differentiation, and apoptosis. Dysregulation of MYC is frequently implicated in tumorigenesis, and its overexpression is associated with poor prognosis in several cancers. However, the transcriptional balance between MYC and its antagonistic partners, such as MAX and members of the MAD family (MXD1-4, MXI1), remains poorly understood in gastric adenocarcinoma. Objectives: To investigate the expression patterns and diagnostic relevance of MYC, MAX, and MXD1-4 in gastric cancer (GC) in comparison to healthy gastric tissue. Methods: We analyzed RNA-seq data from 142 gastric tissue samples. Of these, 74 tumor samples were obtained from patients treated at the Hospital Universitário João de Barros Barreto (CAAE 47580121.9.0000.5634), and 68 normal samples were retrieved from the PRJNA1054173 project, available through the NCBI BioProject database (https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA1054173). Transcript quantification was conducted using Salmon v1.10.1, and differential expression analysis was performed using DESeq2 v1.40.2 in R v4.3.1. Variance stabilizing transformation (VST) was applied for downstream visualizations, including PCA (ggfortify v0.4.16), boxplots (ggplot2 v3.5.1), and heatmaps (ComplexHeatmap v2.18.0). Diagnostic accuracy was evaluated through ROC curves using the pROC v1.18.5 package. Results: A transcriptional imbalance was observed between MYC and the MAX/MAD repressors in gastric tumor samples. MYC was upregulated, while MAX and most MAD genes were downregulated (log2FoldChange > 1 or < -1; padj < 0.05). ROC analysis revealed that all members of the MYC/MAX/MAD family exhibited potential for sample classification, with AUC values exceeding 0.80. These findings were supported by heatmap clustering and PCA, which clearly separated tumor from non-tumor profiles. Conclusion: The MYC/MAX/MAD axis shows a distinct and disrupted expression profile in gastric adenocarcinoma. These transcription factors demonstrate high diagnostic potential and merit further investigation as biomarkers and therapeutic targets in gastric cancer.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
